Whole Genome and Exome Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Workflow, By Application, By End User, By Region & Competition, 2021-2031F

Description

The Global Whole Genome & Exome Sequencing Market is projected to expand significantly, rising from a valuation of USD 3.24 Billion in 2025 to USD 6.93 Billion by 2031, reflecting a compound annual growth rate of 13.51%. This market encompasses technologies and services dedicated to decoding the entire DNA sequence of an organism or its protein-coding exome segments. Growth is primarily underpinned by the rapid reduction in high-throughput sequencing costs and the urgent transition toward precision medicine, which demands extensive genomic profiling for individualized patient treatment. These elements are pivotal in expediting pharmaceutical research and enhancing the precision of clinical diagnostics for complex genetic disorders. According to the Personalized Medicine Coalition, it was reported in 2024 that personalized medicines represented roughly 38 percent of all newly authorized therapeutic molecular entities, underscoring the essential role of genomic data in contemporary drug development.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 3.24 Billion
Market Size 2031	USD 6.93 Billion
CAGR 2026-2031	13.51%
Fastest Growing Segment	Instruments
Largest Market	North America

Nevertheless, the market faces a substantial obstacle in the form of managing and interpreting the immense datasets produced by these sequencing methodologies. The need for extensive computational storage and specialized bioinformatics skills creates a bottleneck for numerous healthcare facilities. Furthermore, strict regulatory requirements concerning data privacy and the ethical management of patient genetic records add complexity to the cross-border exchange of data, potentially constraining the global scalability of collaborative research efforts.

Market Driver

The marked reduction in sequencing expenses and processing times serves as a major engine for market expansion, fueled largely by the deployment of high-throughput systems. These technological advancements enable laboratories to analyze immense genomic libraries at costs significantly lower than in the past, transitioning whole genome sequencing from a specialized research tool to a component of routine clinical practice. This operational evolution establishes a feedback cycle wherein reduced costs drive adoption, encouraging manufacturers to supply advanced instrumentation to diagnostic and research centers. For instance, Illumina reported in its February 2024 financial results that it shipped 352 NovaSeq X units throughout 2023, indicating a robust industry trend toward these more efficient and affordable sequencing solutions.

Simultaneously, the growth of large-scale government genomic programs and research funding is notably boosting the demand for sequencing services. Nations are committing substantial resources to population-level studies aimed at comprehending genetic diversity, which supports continuous workflows for providers and builds the extensive reference databases required for precision medicine. This drive is highlighted by major public health projects that are rapidly digitizing biobanks. According to the National Institutes of Health's February 2024 release regarding the 'All of Us Research Program', the initiative released a dataset comprising 245,388 clinical-grade whole genome sequences to speed up biomedical inquiry. This massive data generation extends to the pharmaceutical sector as well; Regeneron Pharmaceuticals announced in 2024 that its genetics center had sequenced its two millionth exome, demonstrating the colossal volume of data currently defining the global market.

Market Challenge

The intricacies involved in handling and interpreting the vast datasets produced by sequencing technologies represent a major barrier to the growth of the Global Whole Genome & Exome Sequencing Market. As high-throughput technologies yield petabytes of raw data, healthcare institutions often face critical bottlenecks caused by inadequate computational storage and a shortage of bioinformatics professionals. This incapacity to effectively process and analyze genomic data slows the conversion of raw sequences into practical clinical findings, raising operational expenses and hindering research progress. Consequently, the market encounters considerable difficulty in expanding its services to satisfy the rising demand for precision medicine, as essential genetic insights frequently remain locked within isolated or poorly integrated infrastructures.

Highlighting this operational obstacle, data governance persists as a significant issue throughout the life sciences industry. According to the Pistoia Alliance, in 2024, 54 percent of life science experts cited unstructured data as a primary difficulty, while 48 percent noted that the absence of metadata standardization restricts their ability to access and use data efficiently. These figures demonstrate how the immense volume and complexity of genomic data directly impede the speed and effectiveness of drug discovery and diagnostic advancement, thereby constraining the overall growth prospects of the sequencing market.

Market Trends

The shift from short-read to long-read sequencing methodologies is transforming the market, motivated by the necessity to identify structural variants and map complex regions that short-read platforms often overlook. Long-read technologies are becoming increasingly vital for constructing comprehensive reference genomes and resolving phased haplotypes, which significantly improves diagnostic precision for rare diseases. This transition is supported by the commercial uptake of high-throughput long-read instruments. According to Pacific Biosciences' financial results released in February 2024, the company shipped 173 Revio sequencing systems during the fiscal year 2023, indicating a strong industry trend toward adopting these sophisticated technologies.

At the same time, the incorporation of Whole Exome Sequencing (WES) into clinical oncology is becoming a standard practice for thorough tumor profiling. This development enables oncologists to use exome-based biopsies to detect actionable mutations and track treatment resistance more efficiently than limited targeted panels. WES offers a comprehensive examination of somatic changes, which is essential for choosing suitable targeted therapies and immunotherapies. As evidence of this growing reliance on extensive genomic data for precision cancer care, Guardant Health reported in May 2024 that its clinical test volumes reached 46,900, marking a 20 percent year-over-year increase.

Key Market Players

Illumina
Thermo Fisher Scientific
BGI Genomics
Oxford Nanopore Technologies
Pacific Biosciences
Agilent Technologies
QIAGEN
Roche
PerkinElmer
Macrogen

Report Scope

In this report, the Global Whole Genome & Exome Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Whole Genome & Exome Sequencing Market, By Product

Kits
Instruments

Whole Genome & Exome Sequencing Market, By Workflow

Whole Genome Sequencing (WGS)
Whole Exome Sequencing (WES)

Whole Genome & Exome Sequencing Market, By Application

Oncology
Microbial
Non-Invasive Prenatal Testing (NIPT)
Others

Whole Genome & Exome Sequencing Market, By End User

Pharmaceutical and Biotechnology Companies
Diagnostic Laboratories
Hospitals and Clinics
Research and Academic Institutes
Others

Whole Genome & Exome Sequencing Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Whole Genome & Exome Sequencing Market.

Available Customizations:

Global Whole Genome & Exome Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Whole Genome & Exome Sequencing Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Kits, Instruments)
- 5.2.2. By Workflow (Whole Genome Sequencing (WGS) Whole Exome Sequencing (WES))
- 5.2.3. By Application (Oncology, Microbial, Non-Invasive Prenatal Testing (NIPT), Others)
- 5.2.4. By End User (Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Hospitals and Clinics, Research and Academic Institutes, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America Whole Genome & Exome Sequencing Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Workflow
- 6.2.3. By Application
- 6.2.4. By End User
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Whole Genome & Exome Sequencing Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Workflow
    - 6.3.1.2.3. By Application
    - 6.3.1.2.4. By End User
- 6.3.2. Canada Whole Genome & Exome Sequencing Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Workflow
    - 6.3.2.2.3. By Application
    - 6.3.2.2.4. By End User
- 6.3.3. Mexico Whole Genome & Exome Sequencing Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Workflow
    - 6.3.3.2.3. By Application
    - 6.3.3.2.4. By End User

7. Europe Whole Genome & Exome Sequencing Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Workflow
- 7.2.3. By Application
- 7.2.4. By End User
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Whole Genome & Exome Sequencing Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Workflow
    - 7.3.1.2.3. By Application
    - 7.3.1.2.4. By End User
- 7.3.2. France Whole Genome & Exome Sequencing Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Workflow
    - 7.3.2.2.3. By Application
    - 7.3.2.2.4. By End User
- 7.3.3. United Kingdom Whole Genome & Exome Sequencing Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Workflow
    - 7.3.3.2.3. By Application
    - 7.3.3.2.4. By End User
- 7.3.4. Italy Whole Genome & Exome Sequencing Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Workflow
    - 7.3.4.2.3. By Application
    - 7.3.4.2.4. By End User
- 7.3.5. Spain Whole Genome & Exome Sequencing Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Workflow
    - 7.3.5.2.3. By Application
    - 7.3.5.2.4. By End User

8. Asia Pacific Whole Genome & Exome Sequencing Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Workflow
- 8.2.3. By Application
- 8.2.4. By End User
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Whole Genome & Exome Sequencing Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Workflow
    - 8.3.1.2.3. By Application
    - 8.3.1.2.4. By End User
- 8.3.2. India Whole Genome & Exome Sequencing Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Workflow
    - 8.3.2.2.3. By Application
    - 8.3.2.2.4. By End User
- 8.3.3. Japan Whole Genome & Exome Sequencing Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Workflow
    - 8.3.3.2.3. By Application
    - 8.3.3.2.4. By End User
- 8.3.4. South Korea Whole Genome & Exome Sequencing Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Workflow
    - 8.3.4.2.3. By Application
    - 8.3.4.2.4. By End User
- 8.3.5. Australia Whole Genome & Exome Sequencing Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Workflow
    - 8.3.5.2.3. By Application
    - 8.3.5.2.4. By End User

9. Middle East & Africa Whole Genome & Exome Sequencing Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Workflow
- 9.2.3. By Application
- 9.2.4. By End User
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Whole Genome & Exome Sequencing Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Workflow
    - 9.3.1.2.3. By Application
    - 9.3.1.2.4. By End User
- 9.3.2. UAE Whole Genome & Exome Sequencing Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Workflow
    - 9.3.2.2.3. By Application
    - 9.3.2.2.4. By End User
- 9.3.3. South Africa Whole Genome & Exome Sequencing Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Workflow
    - 9.3.3.2.3. By Application
    - 9.3.3.2.4. By End User

10. South America Whole Genome & Exome Sequencing Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Workflow
- 10.2.3. By Application
- 10.2.4. By End User
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Whole Genome & Exome Sequencing Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Workflow
    - 10.3.1.2.3. By Application
    - 10.3.1.2.4. By End User
- 10.3.2. Colombia Whole Genome & Exome Sequencing Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Workflow
    - 10.3.2.2.3. By Application
    - 10.3.2.2.4. By End User
- 10.3.3. Argentina Whole Genome & Exome Sequencing Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Workflow
    - 10.3.3.2.3. By Application
    - 10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Whole Genome & Exome Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Illumina
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific
15.3. BGI Genomics
15.4. Oxford Nanopore Technologies
15.5. Pacific Biosciences
15.6. Agilent Technologies
15.7. QIAGEN
15.8. Roche
15.9. PerkinElmer
15.10. Macrogen